Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia

Patients with familial hypercholesterolemia (FH) are at high or very high risk for cardiovascular disease. Those with heterozygous FH (HeFH) often do not reach low-density lipoprotein cholesterol (LDL-C) targets with statin and ezetimibe therapy, and those with homozygous FH (HoFH) usually require a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomlinson, Brian, Patil, Nivritti Gajanan, Fok, Manson, Lam, Christopher Wai Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Endocrine Society 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090480/
https://www.ncbi.nlm.nih.gov/pubmed/33866776
http://dx.doi.org/10.3803/EnM.2021.964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090480/
https://www.ncbi.nlm.nih.gov/pubmed/33866776
http://dx.doi.org/10.3803/EnM.2021.964

Ejemplares similares